Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Incyte Venture Partners is a venture capital firm established in 2013 and based in San Antonio, Texas. The firm operates under the Targeted Technology Funds brand and focuses on early-stage investments in life sciences and medical technology sectors. Incyte manages the Targeted Technology Fund I, LP, which has a total fund size of $50 million. The firm emphasizes investments in the Southeastern and Southwestern United States, particularly targeting regions such as South Texas, Birmingham, Alabama, and Denver, Colorado.
Since its inception, Incyte has built a portfolio of 31 companies, showcasing its commitment to supporting innovations that enhance healthcare delivery and outcomes. The firm is not to be confused with the publicly traded Incyte Corporation, which is focused on oncology pharmaceuticals. Incyte Venture Partners has a strong track record of backing companies that are poised to make significant impacts in healthcare.
Incyte Venture Partners targets early-stage investments across various sectors, including biotechnology, medical devices, diagnostics, and specialty pharmaceuticals. The firm typically invests in companies at the pre-seed, seed, seed+ (extension), and Series A stages, with check sizes ranging from $500,000 to $1 million. Incyte's investment strategy is centered on identifying innovations that can shorten the time and cost to market while improving clinical outcomes and reducing overall healthcare costs.
The firm seeks to partner with founders who are passionate about their innovations and have a clear vision for their companies. Incyte's hands-on approach allows them to provide operational support and strategic guidance to portfolio companies, leveraging the extensive experience of its management team, which has co-founded and exited multiple medical technology firms.
Incyte Venture Partners has invested in a diverse range of companies within the life sciences and medical technology sectors. Notable portfolio companies include:
Other notable exits from Incyte's portfolio include Vidacare, ENTrigue Surgical, Santalis Pharmaceuticals, NeoSurgical, and ViroXis, showcasing the firm's ability to identify and support successful innovations in the healthcare sector.
To pitch Incyte Venture Partners, founders should visit their website at Incyte Ventures. It is recommended to include a clear overview of the business model, market opportunity, and team background in the pitch deck. Incyte prefers to receive pitches through their website and values warm introductions, although they do not require them.
Response times can vary, but founders should expect to hear back within a few weeks after submission. It is essential to be concise and focused in the pitch materials, emphasizing the innovation's potential impact on healthcare.
Incyte Venture Partners has made significant strides in the venture capital landscape since its founding in 2013. The firm has successfully invested in 31 companies, with notable exits including Vidacare, ENTrigue Surgical, and Santalis Pharmaceuticals. In June 2024, Incyte was involved in the latest observed investment in Gap-Flex, showcasing its ongoing activity in the market.
The firm continues to focus on early-stage life sciences and medical technology investments, maintaining its commitment to supporting innovations that enhance healthcare delivery. As of 2023, Incyte is actively seeking new opportunities within its targeted sectors, reinforcing its position as a key player in the venture capital space.
What are Incyte Venture Partners' investment criteria?
Incyte Venture Partners focuses on early-stage investments in life sciences and medical technology sectors. They typically invest in companies at the pre-seed, seed, seed+ (extension), and Series A stages, with check sizes ranging from $500,000 to $1 million.
How can I pitch to Incyte Venture Partners?
Founders interested in pitching to Incyte can visit their website at Incyte Ventures for more information on the application process and to submit their pitch materials.
What makes Incyte Venture Partners different from other VCs?
Incyte emphasizes a hands-on approach, providing operational support and strategic guidance to portfolio companies. The management team has extensive experience in co-founding and exiting medical technology firms, which enhances their ability to support startups effectively.
What geographic areas does Incyte focus on?
The firm primarily invests in the Southeastern and Southwestern United States, with a particular emphasis on regions such as South Texas, Birmingham, Alabama, and Denver, Colorado.
What is the typical follow-on investment behavior of Incyte?
Incyte Venture Partners is known for its commitment to supporting portfolio companies through subsequent funding rounds, ensuring that they have the necessary resources to grow and succeed in the market.
What sectors does Incyte Venture Partners invest in?
Incyte focuses on sectors such as biotechnology, medical devices, diagnostics, and specialty pharmaceuticals, targeting innovations that can significantly impact healthcare delivery and outcomes.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.